Patents by Inventor Martin Flamant

Martin Flamant has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • USE OF CD9 AS A BIOMARKER AND AS A BIOTARGET IN GLOMERULONEPHRITIS OR GLOMERULOSCLEROSIS
    Publication number: 20220229072
    Abstract: The mechanisms driving the development of extracapillary lesions in focal segmental glomerulosclerosis (FSGS) and crescentic glomerulonephritis (CGN) remain poorly understood. A key question is how parietal epithelial cells (PECs) invade glomerular capillaries, thereby promoting injury and kidney failure. Here the inventors show that expression of the tetraspanin CD9 increases markedly in PECs in mouse models of CGN and FSGS, and in kidneys from individuals diagnosed with these diseases. Cd9 gene targeting in PECs prevents glomerular damage in CGN and FSGS mouse models. Mechanistically, CD9 deficiency prevents the oriented migration of PECs into the glomerular tuft and their acquisition of CD44 and ?1 integrin expression. These findings highlight a critical role for de novo expression of CD9 as a common pathogenic switch driving the PEC phenotype in CGN and FSGS, while offering a potential therapeutic avenue to treat these conditions.
    Type: Application
    Filed: June 3, 2020
    Publication date: July 21, 2022
    Inventors: Pierre-Louis THARAUX, Carole HENIQUE-GRECIET, Martin FLAMANT
  • Method for Renal Transplantation
    Publication number: 20150268219
    Abstract: The present invention is in the technical field of transplantation, and more particularly relates to the prognosis of a renal transplantation, and to the prevention of renal ischemia and reperfusion injury (IRI) prior to renal transplantation. The invention is more particularly based on the findings that the circulating level of ferritin in a patient is predictive of the outcome of renal transplantation, and that an iron administration to said patient prior to transplantation can prevent IRI.
    Type: Application
    Filed: March 24, 2014
    Publication date: September 24, 2015
    Inventors: Ivan CRUZ MOURA, Celine VAUGIER, Martin FLAMANT, Olivier HERMINE
  • Use of an EGFR antagonist for the treatment of glomerolonephritis
    Patent number: 8198266
    Abstract: The present invention relates to uses, methods and compositions for treating immune-mediated glomerulonephritis, such as crescentic glomerulonephritis. More specifically, the invention relates to the use of an EFGR antagonist or of an inhibitor of EGFR or HB-EGF expression for the treatment of said diseases.
    Type: Grant
    Filed: October 31, 2006
    Date of Patent: June 12, 2012
    Assignee: INSERM (Institut National de la Sante et de la Recherche Medicale)
    Inventors: Pierre Louis Tharaux, Martin Flamant
  • Use of an EGFR Antagonist for the Treatment of Glomerolonephritis
    Publication number: 20100104558
    Abstract: The present invention relates to uses, methods and compositions for treating immune-mediated glomerulonephritis, such as crescentic glomerulonephritis. More specifically, the invention relates to the use of an EFGR antagonist or of an inhibitor of EGFR or HB-EGF expression for the treatment of said diseases.
    Type: Application
    Filed: October 31, 2006
    Publication date: April 29, 2010
    Applicant: INSERM (Inetitut National de la Sante et la Recherche Medicale )
    Inventors: Pierre Louis Tharaux, Martin Flamant